midazolam has been researched along with pyrimidinones in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baxter-Meheux, F; Blake, MJ; Eron, JJ; Gaver, VE; Kashuba, AD; Klein, CE; Patterson, KB; Rezk, NL; Rublein, JC; Yeh, RF | 1 |
| Alfaro, RM; Davey, RT; Formentini, E; Penzak, SR; Robertson, SM; Voell, J | 1 |
| Doroshyenko, O; Frank, D; Fuhr, U; Jetter, A; Lütjohann, D; Tomalik-Scharte, D | 1 |
| Doroshyenko, O; Fätkenheuer, G; Frank, D; Fuhr, U; Hein, W; Jetter, A; Kirchheiner, J; Klaassen, T; Schömig, E; Seeringer, A; Wyen, C | 1 |
| Aidasani, DK; Chen, X; Henne, KR; Johnson, MG; Mason, AK; Rock, DA; Stresser, DM; Subramanian, R; Teffera, Y; Tonn, GR; Tran, TB; VandenBrink, BM; Wong, BK; Wong, SG | 1 |
1 trial(s) available for midazolam and pyrimidinones
| Article | Year |
|---|---|
Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Ginkgo biloba; HIV Protease Inhibitors; Humans; Lopinavir; Male; Midazolam; Phytotherapy; Plant Extracts; Protease Inhibitors; Pyrimidinones; Ritonavir; Terfenadine | 2008 |
5 other study(ies) available for midazolam and pyrimidinones
| Article | Year |
|---|---|
Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers.
Topics: Administration, Oral; Adolescent; Adult; Aryl Hydrocarbon Hydroxylases; Biomarkers; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Enzyme Induction; Female; HIV Protease Inhibitors; HIV Seronegativity; Humans; Injections, Intravenous; Intestinal Mucosa; Intestines; Liver; Lopinavir; Male; Midazolam; Middle Aged; Mixed Function Oxygenases; Omeprazole; Pyrimidinones; Ritonavir; Substrate Specificity; Warfarin | 2006 |
New pediatric dosing information for Kaletra.
Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Drug Approval; Drug Interactions; Drug Labeling; HIV Protease Inhibitors; Humans; Infant; Infant, Newborn; Lopinavir; Midazolam; Pediatrics; Pyridines; Pyrimidinones; Pyrones; Sulfonamides; United States; United States Food and Drug Administration | 2008 |
Plasma 4beta-hydroxycholesterol: an endogenous CYP3A metric?
Topics: Administration, Oral; Adult; Benzilates; Cholesterol; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Female; HIV Protease Inhibitors; HIV Seropositivity; Humans; Hydroxycholesterols; Infusions, Intravenous; Lopinavir; Male; Midazolam; Middle Aged; Phenotype; Pyrimidinones; Ritonavir | 2009 |
Do activities of cytochrome P450 (CYP)3A, CYP2D6 and P-glycoprotein differ between healthy volunteers and HIV-infected patients?
Topics: Adolescent; Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; Case-Control Studies; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Dextromethorphan; Digoxin; Down-Regulation; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Midazolam; Middle Aged; Pyrimidinones; Ritonavir; Young Adult | 2010 |
Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme.
Topics: Acetamides; Biotransformation; Cytochrome P-450 CYP3A; Humans; Metabolic Networks and Pathways; Microsomes, Liver; Midazolam; Oxygen; Proteolysis; Pyrimidinones; Quinones; Receptors, CXCR3; Testosterone | 2012 |